ImmunityBio (NASDAQ:IBRX) Shares Gap Up – What’s Next?

ImmunityBio, Inc. (NASDAQ:IBRX)’s share price gapped up before the market opened on Monday . The stock had previously closed at $8.70, but opened at $9.95. ImmunityBio shares last traded at $10.8940, with a volume of 20,609,714 shares trading hands.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ANKTIVA regulatory and commercial footprint expanded, opening more global markets and increasing addressable market for sales growth. ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity
• Positive Sentiment: Company reported a huge revenue jump (reported figures cited between ~671%–700% year‑over‑year) driven by rapid ANKTIVA uptake, which materially changes near‑term commercialization narrative. ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption
• Positive Sentiment: Q4 results beat consensus on revenue and posted a smaller EPS loss than expected, reinforcing that commercial sales are starting to scale. ImmunityBio (NASDAQ:IBRX) Trading 13% Higher After Earnings Beat
• Positive Sentiment: Some brokers increased price targets and reiterated Buy calls (example: D. Boral Capital coverage), supplying additional buy‑side momentum. ImmunityBio Earns Buy Rating from D. Boral Capital
• Neutral Sentiment: Founder Dr. Patrick Soon‑Shiong’s speaking engagements at high‑profile cancer summits increase visibility and credibility but are not an immediate revenue driver. ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute…
• Neutral Sentiment: HC Wainwright and others adjusted estimates: they lowered several near‑term 2026 quarterly EPS forecasts while raising multi‑year targets (FY2028–FY2030), creating mixed signals on timing of profitability. HC Wainwright estimate updates
• Negative Sentiment: Insider selling accelerated this week (director Barry J. Simon and others disclosed sizable sales), which can amplify short‑term downside and signal opportunistic profit‑taking. Insider selling disclosures
• Negative Sentiment: Despite the revenue surge, ImmunityBio remains unprofitable with negative consensus EPS for the current year, leaving valuation and execution risk as investors look for sustained, repeatable profitability. Q4 press release / financials

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. BTIG Research upped their target price on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price target on shares of ImmunityBio in a research report on Monday. Jefferies Financial Group increased their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. HC Wainwright raised their price objective on ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a report on Monday. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, ImmunityBio currently has an average rating of “Moderate Buy” and an average price target of $12.60.

ImmunityBio Trading Down 17.4%

The firm has a market cap of $9.40 billion, a price-to-earnings ratio of -25.11 and a beta of 0.14. The company has a fifty day moving average price of $4.82 and a 200-day moving average price of $3.24.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $38.29 million for the quarter. As a group, research analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Insider Activity at ImmunityBio

In related news, Director Barry J. Simon sold 165,000 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the sale, the director directly owned 2,925,821 shares of the company’s stock, valued at approximately $29,989,665.25. This represents a 5.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Christobel Selecky sold 50,000 shares of ImmunityBio stock in a transaction on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 426,967 shares of company stock valued at $3,565,662. Insiders own 69.48% of the company’s stock.

Institutional Investors Weigh In On ImmunityBio

Several hedge funds have recently modified their holdings of IBRX. Walser Wealth Management Company A Ltd Liability Co acquired a new stake in shares of ImmunityBio during the 4th quarter valued at about $59,000. Invesco Ltd. boosted its position in ImmunityBio by 14.6% during the fourth quarter. Invesco Ltd. now owns 182,836 shares of the company’s stock worth $362,000 after purchasing an additional 23,353 shares in the last quarter. Corient Private Wealth LLC boosted its position in ImmunityBio by 69.7% during the fourth quarter. Corient Private Wealth LLC now owns 333,149 shares of the company’s stock worth $660,000 after purchasing an additional 136,858 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in ImmunityBio in the fourth quarter valued at approximately $35,000. Finally, Empowered Funds LLC acquired a new stake in ImmunityBio in the fourth quarter valued at approximately $28,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.